Net margin is calculated as Net Income divided by its Revenue. Adagene's Net Income for the
six
months ended in Dec. 2025 was €-3.53 Mil. Adagene's Revenue for the
six
months ended in Dec. 2025 was €6.55 Mil. Therefore, Adagene's net margin for the quarter that ended in Dec. 2025 was -53.87%.
The historical rank and industry rank for Adagene's Net Margin % or its related term are showing as below:
FRA:978'
s Net Margin % Range Over the Past 10 Years
Min: -32450.49 Med: -935.44 Max: -104.61
Current: -229.55
FRA:978's Net Margin % is ranked worse than 62.09% of 947
companies
in the Biotechnology industry
Industry Median: -89.33
vs FRA:978: -229.55
Adagene (FRA:978) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
Adagene Net Margin % Related Terms
Adagene Net Margin % Historical Data
* Premium members only.
The historical data trend for Adagene's Net Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:978 vs CNTX, TARA, NVCT: Net Margin % Comparison
For the Biotechnology subindustry, Adagene's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Adagene Net Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Adagene's Net Margin % distribution charts can be found below:
* The bar in red indicates where Adagene's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Adagene (FRA:978) has a Net Margin % of -53.87% as of Dec. 2025. Net margin is the ratio of total net income to net sales. View historical data on Adagene and its competitors. According to the industry distribution chart, Adagene ranks #588 out of 947 companies in the Biotechnology industry, placing it in the top 62.1%.
Is Adagene's Net Margin % too high?
Adagene's current Net Margin % is -53.87%. Based on the distribution chart, Adagene ranks #588 out of 947 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Adagene has a GF Score™ of 42/100, reflecting its overall financial health beyond just this single metric.
How does Adagene's Net Margin % compare to CNTX and TARA?
According to the Biotechnology industry distribution chart, Adagene ranks #588 out of 947 companies for Net Margin %. This places Adagene in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Biotechnology company?
A good Net Margin % depends on the Biotechnology industry context. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Adagene and its competitors. Adagene's current Net Margin % is -53.87%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Adagene stock overvalued right now?
Adagene (FRA:978) has a current Net Margin % of -53.87%. The stock's GF Value™ is €11.04, compared to a current price of €3.32 — trading 69.9% below its estimated fair value. The current Net Margin % is -53.87%. Adagene's overall GF Score™ is 42/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Adagene (FRA:978), the current Net Margin % is -53.87% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Adagene (FRA:978) Overvalued in 2026?
Based on GuruFocus' analysis, Adagene stock appears to be undervalued.
The current stock price of €3.32 is trading 69.9% below its estimated GF Value™ of €11.04.
Key valuation signals for FRA:978:
Net Margin %: -53.87%
GF Value™: €11.04 vs. price of €3.32 (69.9% below fair value)
No single metric tells the full story. See the FRA:978 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Adagene Inc is a platform-driven, clinical-stage biotechnology company focused on the discovery and development of novel antibody-based cancer immunotherapies. The Company leverages computational biology to design and develop novel antibodies. Powered by its Dynamic Precision Library (DPL) platform, which fuels its NEObody, SAFEbody, and POWERbody technologies, it is developing a pipeline of immunotherapies. Its candidate, ADG126 (muzastotug), an anti-CTLA-4 SAFEbody, is in phase 1b/2 and phase 2 clinical development for metastatic microsatellite-stable colorectal cancer. Its clinical-stage products include ADG126 and ADG116, investigational fully human anti-CTLA-4 mAbs generated through SAFEbody and NEObody technologies.
42GF Score
Get the complete analysis for FRA:978
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:978 has been successfully added to your 
